Savant HWP, Inc.
Savant HWP develops products that improve health, maintain wellness and prevent illness.
In September 2012, Savant received a $6.5 million grant from the National Institute on Drug Abuse (“NIDA”) to support the preclinical development of our lead compound, 18-MC for the treatment of cocaine abuse. Savant will seek additional funding from NIDA (up to $20 million) to support the clinical development of 18-MC. This funding is non-dilutive, does not restrict Savant’s freedom to operate and requires no repayment.